Editorial-Orientierung von MedAPI — kein Bestandteil der Kodieranweisung.
C05 covers primary malignant neoplasms arising in the palate, including the hard palate, soft palate, and uvula. Tumor biology and staging framework may differ by subsite: the hard palate is generally considered part of the oral cavity, whereas the soft palate and uvula are commonly evaluated as part of the oropharynx.
Common Histologies
- Squamous cell carcinoma is the predominant malignancy, particularly in the soft palate and uvula.
- Minor salivary gland carcinomas, including adenoid cystic and mucoepidermoid carcinoma, are important considerations, especially for hard-palate masses.
- Less common tumors include adenocarcinoma, mucosal melanoma, lymphoma, and sarcoma. Kaposi sarcoma of the palate is classified separately under C46.2.
Common Symptoms
- Persistent palatal ulcer (K13.79), mass (K13.70), discoloration (K13.70), or induration (K13.70)
- Oral pain (R52), bleeding (R58), dysphagia (R13.11), odynophagia (R07.0), or referred otalgia (H92.09)
- Altered speech (R47.9), hypernasality (R49.21), or nasal regurgitation (R13.12)
- Poorly fitting dentures or loosening of maxillary teeth (Z44.9)
- Trismus (M26.52), cranial neuropathy (G52.9), facial numbness with advanced (R20.0), or perineural disease (G64)
- Cervical lymphadenopathy, particularly with soft-palate or uvular carcinoma (R59.0)
Diagnosis
Evaluation usually includes complete oral cavity and oropharyngeal examination, palpation of the palate and neck, and flexible endoscopy when extension into adjacent pharyngeal structures is possible. Tissue biopsy establishes histology. Contrast-enhanced CT or MRI assesses local extent, bone involvement, perineural spread, and regional nodes; PET/CT may be used for advanced disease or metastatic evaluation.
Staging
Staging depends on the anatomical subsite and histology. Hard-palate carcinomas are generally staged using oral cavity criteria, while soft-palate and uvular squamous cell carcinomas may follow oropharyngeal criteria. Relevant features include tumor size and depth or local invasion, maxillary or skull-base involvement, cervical nodal disease, extranodal extension, and distant metastasis. Minor salivary gland carcinomas may have additional histology-specific prognostic considerations.
Molecular Markers
For squamous cell carcinoma involving the soft palate or uvula, high-risk HPV association may be evaluated, commonly using p16 immunohistochemistry when appropriate under current oropharyngeal cancer guidance. HPV-related staging should not be assumed for hard-palate tumors or non-squamous histologies. Salivary-type carcinomas may undergo targeted molecular testing when results could clarify diagnosis or guide systemic therapy.
Common Treatments
Management is individualized by subsite, stage, histology, functional impact, and resectability:
- Surgical excision, sometimes including maxillectomy or palatal resection, with reconstruction or prosthetic obturation
- Neck dissection when regional nodal treatment is indicated
- Definitive radiation or concurrent chemoradiation, particularly for selected soft-palate or oropharyngeal squamous cell carcinomas
- Postoperative radiation or chemoradiation for adverse pathological features
- Systemic therapy, immunotherapy, or biomarker-directed treatment for recurrent, unresectable, or metastatic disease
- Speech, swallowing, dental, nutritional, and rehabilitation support
Tobacco and alcohol exposure are major risk factors for many palatal squamous cell carcinomas. Where clinically documented and applicable, the classification instructs use of additional codes for alcohol abuse or dependence and for history of tobacco dependence.
Scope Note
C05 identifies the primary anatomical site of a malignant neoplasm of the palate, with child codes distinguishing the hard palate, soft palate, uvula, overlapping palatal sites, and unspecified palate. It does not encode histology, grade, HPV status, TNM stage, nodal involvement, distant metastasis, recurrence, or treatment status. Secondary metastatic involvement of the palate should not be coded as a primary C05 malignancy unless a primary palatal cancer is documented. Kaposi sarcoma of the palate is excluded and classified under C46.2.